Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19
Status:
Recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
Open controlled clinical trial. Hospitalized pediatric patients with COVID-19 will be
included. Upon admission to hospital serum determination of vitamin D, interleukins, ferritin
and Dimer D will be performed. Subsequently, randomization will be performed to identify
which group the patient belongs. Adverse effects will be evaluated on a daily basis. Serum
levels of interleukin (IL) -2, 6, 7,10, ferritin and dimer-D will be taken at the beginning
of hospitalization and on the 7th day after admission. It will be recorded if the patient
presents deterioration of the respiratory function that requires endotracheal intubation and
/ or admission to intensive care and / or if he dies, and at what time of hospitalization
does this outcome occur. The study will culminate when the patient is discharged from
hospitalization.
Phase:
Phase 3
Details
Lead Sponsor:
Coordinación de Investigación en Salud, Mexico
Collaborators:
Hospital General de México Dr. Eduardo Liceaga Hospital Infantil de Mexico Federico Gomez